Here is one key reason that I believe the US market will be buying Incannex well before any clinical results are released. IXHL only has a market capitilization of $68m USD.
Here are three peers trading in the States, and they’re well known.
Compass Pathways $476m USD
Atai Life Sciences $222m USD
MindMed $188m USD
So those three US peers are trading today with an equivalent Aussie price of between 18 cents and 47 cents.
The issue is Aussies are so beaten up on this stock it’s hard to see the wood for the trees. But the new audience in the States doesn’t have that perspective and when they work out Incannex has a massive amount of news coming and they’re also trading at a 62% to 85% discount to comparable companies it’s going to be a very compelling opportunity.
- Forums
- ASX - By Stock
- General discussion
Here is one key reason that I believe the US market will be...
-
- There are more pages in this discussion • 2,739 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)